Pharmacological therapy in gestational diabetes – a comparison between insulin and oral therapy
| Autor: | Eran Hadar, Arnon Wiznitzer, Rony Chen, Eyal Krispin, Yoel Toledano, Elyasaf Shmuel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
medicine.medical_specialty endocrine system diseases Pharmacological therapy medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Pregnancy Internal medicine Diabetes mellitus Glyburide medicine Humans Insulin Hypoglycemic Agents 030212 general & internal medicine Oral therapy Retrospective Studies 030219 obstetrics & reproductive medicine Medical treatment business.industry Infant Newborn nutritional and metabolic diseases Obstetrics and Gynecology medicine.disease Hypoglycemia Gestational diabetes Diabetes Gestational Pediatrics Perinatology and Child Health Gestation Female business |
| Zdroj: | The Journal of Maternal-Fetal & Neonatal Medicine. 35:5071-5079 |
| ISSN: | 1476-4954 1476-7058 |
| DOI: | 10.1080/14767058.2021.1875208 |
| Popis: | The appropriate medical treatment for gestational diabetes mellitus (GDM) is controversial and recommendations vary between different organizations.To compare the safety and efficacy of glyburide and insulin as treatments for GDM.Retrospective analysis of all pregnant women diagnosed with GDM and treated with either glyburide or insulin. Demographic features, clinical characteristics, maternal and neonatal outcomes were compared according to type of pharmacological treatment.Included in the study were 323 women, of whom 269 (83.28%) were treated with glyburide and 54 (16.72%) with insulin. There were no significant differences between the groups, apart from a higher one-hour oral glucose tolerance test (OGTT) value (191.80 mg/dl in the glyburide group, 204.33 in the insulin group,Glyburide is at least as safe and effective as insulin except for higher rates of maternal hypoglycemia. Considering its advantages compared to insulin (ease of use and storage, increased patient responsiveness, and lower cost), it may be considered as first line treatment in GDM, especially when fasting OGTT value is not high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|